Strategic Capital Partner HealthCare Royalty is a growing, KKR-backed royalty monetization and debt financing platform with a track record of over 60 healthcare investments and a $7+ billion commitment across biopharmaceutical assets, signaling strong capacity for large-scale transactions and complex deal structures.

European and US Footprint With offices across New York, Stamford, San Francisco, Boston, London and Miami, HCRx maintains a transatlantic presence that supports cross-border royalty financings and expands potential collaboration opportunities with European and US biopharma players.

Active Deal Flow Recent financings include a $150 million senior secured facility for Apnimed and a $115 million Heidelberg Pharma royalty deal, indicating ongoing appetite for sizable, diversified royalty and revenue participation structures.

Strategic Partners Longstanding collaboration with BridgeBio and a strengthened capital partnership via KKR ownership create solidearned credibility, enabling faster access to capital for development-stage to near-commercial assets and potential co-structuring opportunities.

Targeted Asset Focus HCRx concentrates on assets with meaningful clinical value and durable revenue streams across pharmaceutical, biotechnology and specialty pharma sectors, presenting clear opportunities to explore royalty monetization, debt financing and revenue participation for market-ready assets.